1921
Volume 97, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

This study describes the epidemiological and clinical characteristics of leishmaniasis and the pharmacological treatment of this disease in the municipality of Pueblo Rico, Risaralda, between January 2010 and December 2014. An observational study was conducted using information from the clinical records and epidemiological reports of patients diagnosed and confirmed with leishmaniasis of any age and sex, including sociodemographic, clinical, and pharmacological variables of the therapy received. Univariate and bivariate analyses were performed. A total of 539 cases of leishmaniasis were confirmed, with 29.5% occurring in children under 5 years of age. The median age was 10 years, with predominance in males (55.5%). The indigenous Emberá (aboriginal Americans) were the most affected (50.8%), and 93.3% of cases occurred in people living in scattered rural areas. All lesions corresponded to cutaneous leishmaniasis, of which 251 patients had compromise of the upper limbs (46.6%), 221 of the face (41.0%), and 139 of the lower limbs (25.8%). Pentavalent antimony salts (n-methyl glucamine and sodium stibogluconate) were prescribed in 77.6% ( = 418) of the cases; miltefosine was the second most frequently prescribed medication (21.5%, = 116). The inhabitants of rural areas and the indigenous communities are at a higher risk of acquiring the infection, particularly among infants, which highlights the importance of the biological, social, and demographic factors involved in the disease. There is a need to seek effective public health actions and further research this disease.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0233
2017-11-08
2018-11-15
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/5/tpmd170233.html?itemId=/content/journals/10.4269/ajtmh.17-0233&mimeType=html&fmt=ahah

References

  1. Ministerio de Salud, 2010. Guía de Atención Clínica Integral del Paciente con Leishmaniasis Bogotá, Colombia: Instituto Nacional de Salud, 58. Available at: http://www.ins.gov.co/temas-de-interes/Leishmaniasis%20viceral/02%20Clinica%20Leishmaniasis.pdf. Accessed February 28, 2014.
  2. Piscopo TV, Mallia Azzopardi C, , 2007. Leishmaniasis. Postgrad Med J 83: 649657.[Crossref]
  3. Scott P, , 2011. Leishmania—a parasitized parasite. N Engl J Med 364: 17731774.[Crossref]
  4. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, , 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.[Crossref]
  5. Ministerio de Salud, 2015. Leishmaniasis. Nota descriptiva No. 375. Available at: http://www.who.int/mediacentre/factsheets/fs375/es/. Accessed February 17, 2016.
  6. Kedzierski L, , 2011. Leishmaniasis. Hum Vaccin 7: 12041214.[Crossref]
  7. Medina-Morales DA, Montoya-Franco E, Sanchez-Aristizabal VD, Machado-Alba JE, Rodriguez-Morales AJ, , 2016. Severe and benign Plasmodium vivax malaria in Embera (Amerindian) children and adolescents from an endemic municipality in western Colombia. J Infect Public Health 9: 172180.[Crossref]
  8. Instituto Nacional de Salud, 2013. Estadísticas por Municipio. Sistema Nacional de Vigilancia en Salud Pública - SIVIGILA. Available at: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/EstadsticasSIVIGILA/Forms/public.aspx. Accessed February 28, 2014.
  9. Blanco VM, Cossio A, Martinez JD, Saravia NG, , 2013. Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment. Am J Trop Med Hyg 89: 359364.[Crossref]
  10. Secretaría Departamental de Salud de Risaralda, 2016. Análisis de Situación de Salud con el Modelo de los Determinantes Sociales de Salud (ASIS). Pueblo Rico, Risaralda, Colombia: Municipio de Pueblo Rico. Available at: file:///C:/JorgeMachado/2investigaci%C3%B3n%20audifarma/2-semilleros%20inv/Leishmania/ASIS_Risaralda_2016c.pdf. Accessed February 17, 2016.
  11. Karami M, Doudi M, Setorki M, , 2013. Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran. J Vector Borne Dis 50: 3037.
  12. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.[Crossref]
  13. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N, , 2000. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16: 925950.[Crossref]
  14. Corredor A, 1990. Distribution and etiology of leishmaniasis in Colombia. Am J Trop Med Hyg 42: 206214.[Crossref]
  15. Ferro C, Fuya P, Perez S, Lugo L, Gonzales G, , 2011. Valoración de la ecoepidemiologıa de la leishmaniasis en Colombia a partir de la distribución espacial y ecológica de los insectos vectores [Assessment of the eco-epidemiology of leishmaniasis in Colombia via the spatial and ecological distributions of vector insects]. Biomedica 31: 5059.[Crossref]
  16. Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, Serra A, Cacopardo B, Nunnari G, , 2013. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. BioMed Res Int 2013: 805108.[Crossref]
  17. Rodriguez-Barraquer I, Gongora R, Prager M, Pacheco R, Montero LM, Navas A, Ferro C, Miranda MC, Saravia NG, , 2008. Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia. Am J Trop Med Hyg 78: 276282.
  18. Cardenas R, Sandoval CM, Rodriguez-Morales AJ, Franco-Paredes C, , 2006. Impact of climate variability in the occurrence of leishmaniasis in northeastern Colombia. Am J Trop Med Hyg 75: 273277.
  19. Rodriguez-Morales AJ, , 2011. Climate change, rainfall, society and disasters in Latin America: relations and needs. Rev Peru Med Exp Salud Publica 28: 165166.[Crossref]
  20. Quintero-Herrera LL, 2015. Potential impact of climatic variability on the epidemiology of dengue in Risaralda, Colombia, 2010–2011. J Infect Public Health 8: 291297.[Crossref]
  21. Sundar S, Chakravarty J, , 2015. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 16: 237252.[Crossref]
  22. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG, , 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 195: 602608.[Crossref]
  23. Perilla-Gonzalez Y, Gomez-Suta D, Delgado-Osorio N, Hurtado-Hurtado N, Baquero-Rodriguez JD, Lopez-Isaza AF, Lagos-Grisales GJ, Villegas S, Rodriguez-Morales AJ, , 2014. Study of the scientific production on leishmaniasis in Latin America. Recent Pat Antiinfect Drug Discov 9: 216222.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0233
Loading
/content/journals/10.4269/ajtmh.17-0233
Loading

Data & Media loading...

  • Received : 22 Mar 2017
  • Accepted : 30 Jun 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error